Clinical Trial Data Sharing: IOM Envisions Open And Closed Doors
This article was originally published in The Pink Sheet Daily
Executive Summary
Institute of Medicine report calls for greater, faster availability of full clinical trial data sets, but with no authority and many loopholes, impact on status quo may be minimal.
You may also be interested in...
Vivli Nonprofit Hopes To Be One-Stop Shop For Clinical Trial Data
GlaxoSmithKline, Pfizer, and Biogen are among those participating in new data-sharing and analytics platform; 2,500 trials currently available to researchers.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.
Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests
The rulemaking is supposed to formalize the Patent Trial and Appeal Board process, which has been in an interim status since a Supreme Court decision, giving manufacturers more ability to request oversight of the decisions.